Professor

Chikashi ISHIOKA

Associate Professor

Syunsuke KATO

Assistant Professor

Yuichi KAKUDO

Senior Assistant Professor

Hideki SHIMODAIRA

Assistant Professor

Shin TAKAHASHI

Assistant Professor

Hisatsugu OHORI

Assistant Professor

Shoko AKIYAMAI

Assistant Professor

Kozue YOSHIDAI

Research Associate

Yasuhiro SAKAMOTO

Assistant Professor

Masatoshi SHIONO

Mission

The department was founded in 1969 to contribute to human welfare through cancer treatment research.

History

This division, founded in 1969, is one of the oldest department of medical oncology in universities in Japan . The department's first professor, Tatsuo Saito set up the criteria to evaluate the effects of cancer therapeutic agents clinically. During the first decade, a large number of drugs were developed and the clinical effects of these drugs were studied in phase trials introduced from the U. S by him. The effects of combination therapies were also examined, but the efficacy were limited. In 1978, As Dr.Saito's successor, Akira Wakui extended the research field into basic science. Intensive studies were carried out on drug sensitivity, drug resistance and drug delivery. Based on these studies, new strategies were developed and were applied in practice with remarkable effects in some cases. In 1991, Ryunosuke Kanamaru became the department's professor and in 1993, the Institute was reorganized as the Institute of Development, Aging and Cancer that now includes our department. In 2000,accompanied by the closure of the Attached hospital the clinical part was moved to the Affiliated Hospital of medical school. In 2003, Chikashi Ishioka became current research is focused on translational research of molecular oncology and chemotherapy including molecular-target therapy.

Research Interest

1. Optimization of administration of anti-cancer drugs based on molecular diagnosis.

   Recent advances in molecular diagnostics such as sequence-based mutation analysis and genome-wide expression analysis would enable the novel approach to predict cancer chemosensitivity or drug-resistance, and therefore, efficient application of chemotherapy to cancer patients. Using DNA microarray analysis, we are developing predictive expression profiles that are highly correlated with specific chemotherapeutic treatments by using both tumor cell lines and cancer tissues from patients.

2. Development of molecular diagnostics for cancer-risk assessment, origin of tumors unknown primary sites, and prediction of prognosis.

   Studies on the evaluation of cancer-risk for individuals are important for prevention and early detection of cancers. We have performed collaborative studies to develop systems on genetic testing for both familial breast cancer and hereditary colorectal cancers. Tumors unknown primary sites are not rare and approximately 20 patients visit to our clinical section every year. Because of unknown primary sites, initial trials of chemotherapy were often unsuccessful. We are trying to develop a diagnostic system to predict specific expression profiles similar to primary tumors by multiclass analysis.

3. Studies on development of molecular target therapy for cancer.

   Current molecular target therapeutics mainly focused on receptor tyrosine kinases including, Bcr-Abl, c-kit, EGFR and CD20. Although these are successfully applied in cancer clinic, it is necessary to develop novel molecular targets and drugs that enable to modulate protein functions to regulate most of common cancers. We have focused on proteins derived from tumor suppressor genes (p53, PTEN and BRCA1) and human mismatch repair genes (MLH1 and MSH2) and have studied on possible mechanisms that restore or modulate the normal or mutated protein function to accelerate efficient cell death in cancer cells.

4. Clinical studies on cancer chemotherapy of gastrointestinal malignancies.

   During last four decades, we have performed multiple studies on cancer chemotherapy for patients with gastrointestinal malignancies, including esophageal, stomach and colorectal cancers. At present, we have focused on i) clinical phase II study on chemo-radio therapy of stage II or III eshophageal cancer as a institutional collaborative study, ii) clinical phase II of advanced gastric cancer for irrinotecan and docetaxel combination chemotherapy, iii) other combination chemotherapy regimens for colorectal cancers and other primary tumors.

5. Qualitative cancer imaging by positron emission tomography (PET) and its application to the evaluation of efficacy of cancer treatment.

   During last 2 decades, we have used 18FDG PET for qualitative diagnosis of tumors (especially gastrointestinal malignancies) and quantitative evaluation of responses against anti-cancer drugs. The efforts are now applying to the assessment of responses in novel molecular-targeted anticancer drugs.

6. Studies on molecular mechanism of cancers using model mouse systems and their application to cancer chemoprevention.

   Using APC gene knockout mice and a mouse genetic system, we have studied on genetic and biochemical mechanisms underlying colorectal carcinogenesis. During this process, we have found novel genes that negatively modulate the carcinogenesis. The gene product and its molecular pathway have been considered as a novel molecular target for molecular and chemoprevention of human colorectal cancers.

(Click for larger image.)

(Click for larger image.)

(Click for larger image.)

(Click for larger image.)

Publication

1. Ransburgh, D. J.，Chiba, N.，Ishioka, C.，Toland, A. E.，Parvin, J. D. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res 70: 988-95 (2010)
2. Shimbo, T.，Fukui, T.，Ishioka, C.，Okamoto, K.，Okamoto, T.，Kameoka, S.，Sato, A.，Toi, M.，Matsui, K.，Mayumi, T.，Saji, S.，Miyazaki, M.，Takatsuka, Y.，Hirata, K. Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology. Int J Clin Oncol (2010)
3. Yamakoshi, H.，Ohori, H.，Kudo, C.，Sato, A.，Kanoh, N.，Ishioka, C.，Shibata, H.，Iwabuchi, Y. Structure-activity relationship of C(5)-curcuminoids and synthesis of their molecular probes thereof. Bioorg Med Chem 18: 1083-1092 (2010)
4. Ariga, H.，Nemoto, K.，Miyazaki, S.，Yoshioka, T.，Ogawa, Y.，Sakayauchi, T.，Jingu, K.，Miyata, G.，Onodera, K.，Ichikawa, H.，Kamei, T.，Kato, S.，Ishioka, C.，Satomi, S.，Yamada, S. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 75: 348-56 (2009)
5. Ishida, T.，Kiba, T.，Takeda, M.，Matsuyama, K.，Teramukai, S.，Ishiwata, R.，Masuda, N.，Takatsuka, Y.，Noguchi, S.，Ishioka, C.，Fukushima, M.，Ohuchi, N. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol 64: 361-9 (2009)
6. Naruse, H.，Ikawa, N.，Yamaguchi, K.，Nakamura, Y.，Arai, M.，Ishioka, C.，Sugano, K.，Tamura, K.，Tomita, N.，Matsubara, N.，Yoshida, T.，Moriya, Y.，Furukawa, Y. Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay. Fam Cancer 8: 509-517 (2009)
7. Nomizu, T.，Sakuma, T.，Yamada, M.，Matsuzaki, M.，Katagata, N.，Watanabe, F.，Nihei, M.，Ishioka, C.，Takenoshita, S.，Abe, R. Three cases of kindred with familial breast cancer in which carrier detection by BRCA gene testing was performed on family members. Breast Cancer (2009)
8. Sakayauchi, T.，Nemoto, K.，Ishioka, C.，Onishi, H.，Yamamoto, M.，Kazumoto, T.，Makino, M.，Yonekura, R.，Itami, J.，Sasaki, S.，Suzuki, G.，Hayabuchi, N.，Tamamura, H.，Onimaru, R.，Tamamoto, T.，Yamada, S. Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer. Jpn J Radiol 27: 257 (2009)
9. Sakayauchi, T.，Nemoto, K.，Ishioka, C.，Onishi, H.，Yamamoto, M.，Kazumoto, T.，Makino, M.，Yonekura, R.，Itami, J.，Sasaki, S.，Suzuki, G.，Hayabuchi, N.，Tamamura, H.，Onimaru, R.，Yamada, S. Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer. Jpn J Radiol 27: 131-7 (2009)
10. Shibata, H.，Yamakoshi, H.，Sato, A.，Ohori, H.，Kakudo, Y.，Kudo, C.，Takahashi, Y.，Watanabe, M.，Takano, H.，Ishioka, C.，Noda, T.，Iwabuchi, Y. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci 100: 956-60 (2009)
11. Watanabe, G.，Kato, S.，Nakata, H.，Ishida, T.，Ohuchi, N.，Ishioka, C. alphaB-crystallin: A novel p53-target gene required for p53-dependent apoptosis. Cancer Sci 100: 2368-2375 (2009)
12. Yoshioka, T.，Kato, S.，Gamoh, M.，Chiba, N.，Suzuki, T.，Sakayori, M.，Kato, S.，Shibata, H.，Shimodaira, H.，Otsuka, K.，Kakudo, Y.，Takahashi, S.，Ishioka, C. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Britishi Jouranal of Cancer 101: 1972-1977 (2009)
13. Shibata, H., Yamakoshi, H., Sato, A., Ohori, H., Kakudo, Y., Kudo, C., Takahashi, Y., Watanabe, M., Takano, H., Ishioka, C., Noda, T., Iwabuchi, Y. [in press] Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci 100 (2009)
14. Marinovic-Terzic, I., Yoshioka-Yamashita, A., Shimodaira, H., Avdievich, E., Hunton, I.C., Kolodner, R.D., Edelmann, W., Wang, J.Y. Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. Proc Natl Acad Sci U S A 105: 13993-13998 (2008)
15. Berglind, H., Pawitan, Y., Kato, S., Ishioka, C., Soussi, T. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 7 (2008)
16. Takahashi, S., Moriya, T., Ishida, T., Shibata, H., Sasano, H., Ohuchi, N., Ishioka, C. Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci 99: 324-332 (2008)
17. Ishida, T., Kiba, T., Takeda, M., Matsuyama, K., Teramukai, S., Ishiwata, R., Masuda, N., Takatsuka, Y., Noguchi, S., Ishioka, C., Fukushima, M., Ohuchi, N. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol (2008)
18. Wei, L., Lan, L., Hong, Z., Yasui, A., Ishioka, C., Chiba, N. Rapid Recruitment of BRCA1 to DNA Double-Strand Breaks Is Dependent on Its Association with Ku80. Mol Cell Biol 28: 7380-7393 (2008)
19. Shibata, H., Takano, H., Ito, M., Shioya, H., Hirota, M., Matsumoto, H., Kakudo, Y., Ishioka, C., Akiyama, T., Kanegae, Y., Saito, I., Noda, T. Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci U S A 104: 18199-18204 (2007)
20. Takahashi, M., Shimodaira, H., Andreutti-Zaugg, C., Iggo, R., Kolodner, R.D., Ishioka, C. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res 67: 4595-4604 (2007)
21. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., Olivier, M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629 (2007)
22. Otsuka, K., Kato, S., Kakudo, Y., Mashiko, S., Shibata, H., Ishioka, C. The screening of the second-site suppressor mutations of the common p53 mutants. Int J Cancer 121: 559-566 (2007)
23. Ohori, H., Yamakoshi, H., Tomizawa, M., Shibuya, M., Kakudo, Y., Takahashi, A., Takahashi, S., Kato, S., Suzuki, T., Ishioka, C., Iwabuchi, Y., Shibata, H. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006 5: 2563-2571 (2006)
24. Yamaura, G., Yoshioka, T., Fukuda, H., Yamaguchi, K., Suzuki, M., Furumoto, S., Iwata, R., Ishioka, C. O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine. Eur J Nucl Med Mol Imaging 33: 1134-1139 (2006)
25. Inoue, K., Okada, K., Harigae, H., Taki, Y., Goto, R., Kinomura, S., Kato, S., Kaneta, T., Fukuda, H. Diffuse Bone Marrow Uptake on F-18 FDG PET in Patients With Myelodysplastic Syndromes. Clinical Nuclear Medicine 31: 721-723 (2006)
26. Iacopetta, B., Russo, A., Bazan, V., Dardanoni, G., Gebbia, N., Soussi, T., Kerr, D., Elsaleh, H., Soong, R., Kandioler, D., Janschek, E., Kappel, S., Lung, M., Leung, C.S., Ko, J.M., Yuen, S., Ho, J., Leung, S.Y., Crapez, E., Duffour, J., Ychou, M., Leahy, D.T., O'Donoghue, D.P., Agnese, V., Cascio, S., Di Fede, G., Chieco-Bianchi, L., Bertorelle, R., Belluco, C., Giaretti, W., Castagnola, P., Ricevuto, E., Ficorella, C., Bosari, S., Arizzi, C.D., Miyaki, M., Onda, M., Kampman, E., Diergaarde, B., Royds, J., Lothe, R.A., Diep, C.B., Meling, G.I., Ostrowski, J., Trzeciak, L., Guzinska-Ustymowicz, K., Zalewski, B., Capella, G.M., Moreno, V., Peinado, M.A., Lonnroth, C., Lundholm, K., Sun, X.F., Jansson, A., Bouzourene, H., Hsieh, L.L., Tang, R., Smith, D.R., Allen-Mersh, T.G., Khan, Z.A., Shorthouse, A.J., Silverman, M.L., Kato, S., Ishioka, C. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 17: 842-847 (2006)
27. Mathe, E., Olivier, M., Kato, S., Ishioka, C., Hainaut, P., Tavtigian, S.V. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34: 1317-1325 (2006)
28. Soussi, T., Asselain, B., Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Beroud, C. Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection. Clin Cancer Res 12: 62-69 (2006)
29. Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Beroud, C., Soussi, T. The UMD TP53 database and website: update and revisions. Hum Mutat 27: 14-20 (2006)
30. Soussi, T., Ishioka, C., Claustres, M., Beroud, C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 6: 83-90 (2006)
31. Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bieche, I., Varley, J., Bignon, Y., Uhrhammer, N., Winqvist, R., Jukkola-Vuorinen, A., Niederacher, D., Kato, S., Ishioka, C., Hainaut, P., Borresen-Dale, A. The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer. Clin Cancer Res 12: 1157-1167 (2006)
32. Soussi, T., Rubio-Nevado, J.M., Ishioka, C. MUT-TP53: a versatile matrix for TP53 mutation verification and publication. Hum Mutat 27: 1151-1154 (2006)
33. Yamaguchi, K., Shimamura, T., Komatsu, Y., Takagane, A., Yoshioka, T., Saitoh, S., Munakata, M., Sato, T., Arai, T., Saitoh, H. Phase I - I I study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer. Gastric Cancer: 36-43 (2006)
34. Mathe, E., Olivier, M., Kato, S., Ishioka, C., Vaisman, I., Hainaut, P. Predicting the Transactivation Activity of p53 Missense Mutants Using a Four-Body Potential Score Derived From Delaunay Tessellations. Hum Mutat 27: 163-172 (2006)
35. Yoshioka, T., Sakayori, M., Kato, S., Chiba, N., Miyazaki, S., Nemoto, K., Shibata, H., Shimodaira, H., Ohtsuka, K., Kakudo, Y., Sakata, Y., Ishioka, C. A dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil and radiation. Int J Clin Oncol 11: 454-460 (2006)
36. Kawaguchi, T., Kato, S., Otsuka, K., Watanabe, G., Kumabe, T., Tominaga, T., Yoshimoto, T., Ishioka, C. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 24: 6976-6981 (2005)
37. Kakudo, Y., Shibata, H., Otsuka, K., Kato, S., Ishioka, C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 65: 2108-2114 (2005)
38. Chiba, N., Yoshioka, T., Sakayori, M., Yoshiki, M., Miyazaki, S., Akiyama, S., Otsuka, K., Yamaura, G., Shibata, H., Kato, S., Kato, S., Ishioka, C. AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report. Anticancer Res 25: 2965-2968 (2005)
39. Starita, L.M., Horwitz, A.A., Keogh, M.C., Ishioka, C., Parvin, J.D., Chiba, N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 280: 24498-24505 (2005)
40. Soussi, T., Kato, S., Levy, P.P., Ishioka, C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 25: 6-17 (2005)
41. You, F., Chiba, N., Ishioka, C., Parvin, J.D. Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells. Oncogene 23: 5792-5798 (2004)
42. Shiraishi, K., Kato, S., Han, S.Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., Ishioka, C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279: 348-355 (2004)
43. Kato, H., Fujimura, M., Kumabe, T., Ishioka, C., Kanamaru, R., Yoshimoto, T. PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci 11: 37-41 (2004)
44. Yamaura, G., Yoshioka, T., Kubota, K., Yamaguchi, K., Iwata, R., Abe, T., Kitagawa, Y., Kanamaru, R., Fukuda, H., Ishioka, C. FDG - PET and gallium scintigraphy for diagnosis of an advanced jejunal adenocarcinoma with distant metastases. Clin Nucl Med 29: 825-827 (2004)
45. Takahashi, M., Sakayori, M., Takahashi, S., Kato, T., Kaji, M., Kawahara, M., Suzuki, T., Kato, S., Kato, S., Shibata, H., Murakawa, Y., Yoshioka, T., Ishioka, C. A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer. J Gastroenterol 39: 1210-1214 (2004)
46. Akiyama, S., Yonezawa, T., Kudo, T.A., Li, M.G., Wang, H., Ito, M., Yoshioka, K., Ninomiya-Tsuji, J., Matsumoto, K., Kanamaru, R., Tamura, S., Kobayashi, T. Activation mechanism of c-Jun amino-terminal kinase in the course of neural differentiation of P19 embryonic carcinoma cells. J Biol Chem 279: 36616-36620 (2004)
47. Kawahara, M., Sakayori, M., Shiraishi, K., Nomizu, T., Takeda, M., Abe, R., Ohuchi, N., Takenoshita, S., Ishioka, C. Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families. J Hum Genet 49: 391-395 (2004)
48. Takeda, M., Ishida, T., Ohnuki, K., Suzuki, A., Sakayori, M., Ishioka, C., Nomizu, T., Noguchi, S., Matsubara, Y., Ohuchi, N. Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan. Breast Cancer 11: 30-32 (2004)
49. Yoshioka, T., Yamaguchi, K., Kubota, K., Saginoya, T., Yamazaki, T., Ido, T., Yamaura, G., Takahashi, H., Fukuda, H., Kanamaru, R. Evaluation of 18F-FDG PET in patients with a, metastatic, or recurrent gastric cancer. J Nucl Med 44: 690-699 (2003)
50. Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R.D., Wang, J.Y. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A 100: 2420-2425 (2003)
51. Kato, S., Han, S.Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., Ishioka, C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100: 8424-8429 (2003)
52. Ohtsu, A., Boku, N., Yoshioka, T., Hyodo, I., Shirao, K., Shimada, Y., Saitoh, S., Nakamura, A., Yamamichi, N., Yamamoto, S., Yoshida, S. A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). Jpn J Clin Oncol 33: 28-32 (2003)
53. Otsuka, K., Suzuki, T., Shibata, H., Kato, S., Sakayori, M., Shimodaira, H., Kanamaru, R., Ishioka, C. Analysis of the human APC mutation spectrum in a saccharomyces cerevisiae strain with a mismatch repair defect. Int J Cancer 103: 624-630 (2003)
54. Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Momiyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A., Nakamura, A., Kanazawa, K., Tan-Takeuchi, K., Iwasaki, K., Yokoyama, W.M., Kudo, A., Fujiwara, M., Asou, H., Takai, T. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest 111: 323-332 (2003)
55. Yoshioka, T. Mini review- The present state of the chemotherapy for advanced gastric cancer. Annals of Cancer Research and Therapy 11: 143-152 (2003)
56. Sakayori, M., Kawahara, M., Shiraishi, K., Nomizu, T., Shimada, A., Kudo, T., Abe, R., Ohuchi, N., Takenoshita, S., Kanamaru, R., Ishioka, C. Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer. J Hum Genet 48: 130-137 (2003)
57. Yoshioka, T., Sakata, Y., Terashima, M., Sekikawa, K., Gamoh, M., Mitachi, Y., Saitoh, S., Kanamaru, R. Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. Gastric Cancer 6: 153-158 (2003)
58. Gallagher, R.C., Hay, T., Meniel, V., Naughton, C., Anderson, T.J., Shibata, H., Ito, M., Clevers, H., Noda, T., Sansom, O.J., Mason, J.O., Clarke, A.R. Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency. Oncogene 21: 6446-6457 (2002)
59. Murakawa, Y., Satake, N., Kato, S., Yoshioka, T., Kanamaru, R. a-FP Normalization as a prognostic factor for mediastinal origin embryonal carcinoma: report of five cases. Internal Medicine 41: 883-888 (2002)
60. Kobayashi, K., Hino, M., Fukuoka, M., Takeuchi, K., Furuse, K., Yoneda, S., Hasegawa, K., Noda, K., Kinoshita, H., Kimura, I., Taguchi, T., Kanamaru, R., Horikoshi, N., Niitani, H. Phase1 studies of nogitecan hydrochloride for japanese. Int. J. Clin. Oncol. 7: 177-186 (2002)
61. Hasegawa, S., Sato, T., Akazawa, H., Okada, H., Maeno, A., Ito, M., Sugitani, Y., Shibata, H., Miyazaki, J., Katsuki, M., Yamauchi, Y., Yamamura, K., Katamine, S., Noda, T. Apoptosis in neural crest cells by functional loss of APC tumor suppressor gene. Proc. Natl. Acad. Sci. USA 99: 297-302 (2002)
62. Chiba, N., Parvin, J.D. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. Cancer Research 62: 4222-4228 (2002)
63. Yoshioka, T., Yamaguchi, K., Kubota, K., Saginoya, T., Yamazaki, T., Ido, T., Takahashi, H., Oikawa, H., Fukuda, H., Kanamaru, R. FDG-PET in gastric cancer with meastasis or recurrence. J. Nucl. Med. 43: 67 (2002)
64. Tsuchida, R., Yamada, T., Takagi, M., Shimada, A., Ishioka, C., Katsuki, Y., Igarashi, T., Chessa, L., Delia, D., Teraoka, H., Mizutani, S. Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast. Radiation Research 158: 195-201 (2002)
65. Sakaguchi, A., Miyaike, M., Karoda, K., Nozaki, N., Tanaka, M., Hibino, M., FUjii, Y., Kato, S., Kikuchi, A. Epitope distribution of randomly established monoclonal antibodies against human type ・ DNA topoisomerases. J. Biochem 132: 409-416 (2002)
66. Hanada, M., Ninomiya-Tsuji, J., Komaki, K., Ohnishi, M., Katsura, K., Kanamaru, R., Matsumoto, K., Tamura, S. Regulation of the TAK1 signaling pathway by protein phosphatase 2C. J. Biol. Chem. 276: 5753-5759 (2001)
67. Tashiro, M., Kubota, K., Itoh, M., Nakagawa, Y., Kamada, M., Takahashi, Y., Yoshioka, T., Masud, M., Sasaki, H. Regional cerebral glucose metabolism of patients with malignant diseases in different clinical phases. Med. Sci. Monit. 7: 226-232 (2001)
68. Chiba, N., Parvin, J.D. Redistribution of BRCA1 among four different protein complexes following replication blockage. J. Biol. Chem. 246: 38549-38554 (2001)
69. Shafman, T.D., Levitz, S., Nixon, A.J., Gibans, L.A., Nichols, K.E., Bell, D.W., Ishioka, C., Isselbacher, K.J., Gelman, R., Garber, J., Harris, J.R., Haber, D.A. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes, Chromosomes & Cancer 27: 124-129 (2000)
70. Mukouyama, Y., Chiba, N., Hara, T., Okada, H., Ito, Y., Kanamaru, R., Miyajima, A., Satake, M., Watanabe, T. The AML1 transcription factor functions to develop and maintain hematogenic precursor cells in the embryonic aorta-gonad-mesonephros region. Dev. Biol. 220: 27-36 (2000)
71. Chiba, N., Suldan, Z., Freedman, L.P., Parvin, J.D. Binding of liganded vitamin D receptor to the vitamin D receptor interacting protein coactivator complex induces interaction with RNA polymerase ・ holoenzyme. J. Biol. Chem. 275: 10719-10722 (2000)
72. Han, S.Y., Kato, H., Kato, S., Suzuki, T., Shibata, H., Ishii, S., Shiiba, K., Matsuno, S., Kanamaru, R., Ishioka, C. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 60: 3147-3151 (2000)
73. Kikuchi, H., Ujiie, S., Kanamaru, R. Osteomalacia that became symptomatic 13 years after a total gastrectomy. Internal Med. 39: 394-396 (2000)